Escuven (aescin) gel 1% 30 g.


Manufacturer: Ukraine

Varicose veins, leg swelling and pain associated with venous insufficiency, post-traumatic hematomas and hematomas after injections and infusions.



Escuven gel Composition:

active substance: aescin; 1 g of gel contains 10 mg of amorphous β-escin;
excipients: carbomer, propylene glycol, triethanolamine, methylparaben (E 218), ethanol 96%, purified water.

Dosage form. Gel 1%.
Basic physical and chemical properties: colorless or with a yellowish tinge, slightly opalescent, transparent homogeneous gel.

Pharmacotherapeutic group.

Angioprotectors. Capillary stabilizing agents. ATX code С05С X03.

Pharmacological properties.

Escuven gel Pharmacodynamics.

Escin is a natural mixture of triterpene saponins obtained from horse chestnut seeds (Aesculus hippocastanum L.), which have decongestant, venotonic properties and anti-inflammatory activity. In addition, escin acts at the initial stage of the inflammatory process associated with increased membrane and capillary permeability and the production of exudate into adjacent tissues.

Escin reveals antiserotonin and antihistamine effects.

Escin inhibits the activity of prostaglandin synthetase. This enzyme is required for the formation of prostaglandins, which play an important role in the mechanism of inflammation.

Escin prevents a decrease in ATP in endothelial cells and increases the activity of phospholipase A2, an enzyme responsible for the release of precursors of inflammatory mediators.

Escin reduces the activity of lysosomal enzymes that break down proteoglycans, which are contained in the capillary walls. This increases the resistance of the capillaries, reduces their permeability, thereby reducing the amount of exudate and the formation of edema.


Has not been studied.

Escuven gel Clinical characteristics.

Indications. Varicose veins, leg edema and pain associated with venous insufficiency, post-traumatic hematomas and hematomas after injections and infusions.


Hypersensitivity to the components of the drug, skin damage (for example, burns, eczema, open wounds).

Interaction with other medicinal products and other types of interactions. Unknown. It is not recommended to use the gel on one area of ​​the skin together with other topical products.

Features of the application. The gel should not be applied to inflamed skin, open wounds and mucous membranes. Do not rub when applied. If you develop skin inflammation, thrombophlebitis, severe pain, sudden swelling of one or both legs, heart or kidney failure, seek immediate medical attention. In case of sudden onset of severe symptoms of venous insufficiency (edema, discoloration of the skin, feeling of tension and pain), especially in one limb, it is necessary to exclude venous thrombosis of the lower extremities.

The use of the gel for varicose veins is not a substitute for other preventive or therapeutic measures (for example, wearing supportive elastic stockings, dousing with cold water).

Avoid contact of the gel with eyes and mucous membranes. Wash hands thoroughly after each gel application.

The gel contains methylparaben (E 218), which can cause an allergic reaction (including a delayed one), and in exceptional cases – bronchospasm, and propylene glycol (E 1520), which can cause skin irritation.

Application during pregnancy or lactation. Due to the lack of relevant data, Escuven® gel should not be used during pregnancy and lactation.

The ability to influence the reaction rate when driving vehicles or other mechanisms. Does not affect.

Method of administration and dosage. Apply the gel in a thin layer to the damaged area of ​​the skin and around it 2-3 times a day. Should not be rubbed.
In case of varicose veins, the simultaneous use of an elastic bandage or elastic stockings is recommended.
The duration of treatment depends on the severity of the therapeutic effect. If after 14 days of therapy there is no improvement, you need to see a doctor.


The experience of using the drug for children is not enough, therefore it is not recommended to use it in patients of this age category.


There is no data on overdose.